We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+22.98%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.69B
AUM Growth
+$481M
Cap. Flow
+$129M
Cap. Flow %
4.79%
Top 10 Hldgs %
44.27%
Holding
113
New
25
Increased
16
Reduced
30
Closed
12

Top Buys

Rank Stock Value
1
KO icon
Coca-Cola
KO
+$32.8M
2
AAPL icon
Apple
AAPL
+$32.1M
3
AVBP icon
ArriVent BioPharma
AVBP
+$31.5M
4
ARGX icon
argenx
ARGX
+$26.4M
5
CRH icon
CRH
CRH
+$25.7M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$55.4M
2
RPRX icon
Royalty Pharma
RPRX
+$48.3M
3
LVS icon
Las Vegas Sands
LVS
+$36.3M
4
MSFT icon
Microsoft
MSFT
+$33.4M
5
TERN
Terns Pharmaceuticals
TERN
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 57.97%
2 Technology 7.85%
3 Communication Services 7.05%
4 Consumer Discretionary 4.46%
5 Financials 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GE icon
26
GE Aerospace
GE
$384B
$36.4M 1.35%
259,931
-186,363
-42% -$22M
KO icon
27
Coca-Cola
KO
$375B
$33.4M 1.24%
+546,500
New +$32.8M
MSFT icon
28
Microsoft
MSFT
$3.71T
$33.4M 1.24%
79,317
-82,607
-51% -$33.4M
STRO icon
29
Sutro Biopharma
STRO
$421M
$32.6M 1.21%
577,819
– –
MCK icon
30
McKesson
MCK
$101B
$30.4M 1.13%
56,639
-6,821
-11% -$3.46M
AAPL icon
31
Apple
AAPL
$4.57T
$30.3M 1.13%
+176,680
New +$32.1M
CRH icon
32
CRH
CRH
$66.8B
$28.9M 1.08%
+335,580
New +$25.7M
AVBP icon
33
ArriVent BioPharma
AVBP
$1.44B
$27.9M 1.04%
+1,563,709
New +$31.5M
FULC icon
34
Fulcrum Therapeutics
FULC
$297M
$26.9M 1%
2,848,486
-2,670,395
-48% -$23.8M
ELV icon
35
Elevance Health
ELV
$85.5B
$26.4M 0.98%
50,925
-2,810
-5% -$1.4M
ORCL icon
36
Oracle
ORCL
$423B
$24.7M 0.92%
196,674
-125,376
-39% -$14.3M
CMG icon
37
Chipotle Mexican Grill
CMG
$41.5B
$23.2M 0.86%
398,500
-37,000
-8% -$1.89M
BCYC
38
Bicycle Therapeutics
BCYC
$292M
$22.8M 0.85%
914,476
– –
PEPG icon
39
PepGen
PEPG
$197M
$22.4M 0.83%
1,520,932
+1,034,321
+213% +$12.2M
BSX icon
40
Boston Scientific
BSX
$71.5B
$20.8M 0.77%
303,035
-391,066
-56% -$25.1M
FATE icon
41
Fate Therapeutics
FATE
$326M
$18.8M 0.7%
+2,562,852
New +$15.9M
RCUS icon
42
Arcus Biosciences
RCUS
$3.64B
$18.1M 0.67%
957,304
– –
HLT icon
43
Hilton Worldwide
HLT
$71.5B
$16.7M 0.62%
78,502
-30,760
-28% -$6.05M
CRM icon
44
Salesforce
CRM
$158B
$16.6M 0.62%
+55,050
New +$15.9M
SBUX icon
45
Starbucks
SBUX
$120B
$15.8M 0.59%
+172,951
New +$16.1M
JNJ icon
46
Johnson & Johnson
JNJ
$625B
$14.3M 0.53%
90,097
– –
GPN icon
47
Global Payments
GPN
$22.8B
$14.2M 0.53%
106,094
-6,286
-6% -$831K
PINS icon
48
Pinterest
PINS
$13.4B
$13.7M 0.51%
+395,851
New +$14.4M
MREO
49
Mereo BioPharma
MREO
$47.3M
$12.1M 0.45%
3,653,494
-3,717,344
-50% -$12.6M
SNY icon
50
Sanofi
SNY
$104B
$10.2M 0.38%
210,701
+39,700
+23% +$1.94M
1
2
3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Suvretta Capital Management held 113 positions worth $2.69B, up 22% from $2.21B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Suvretta Capital Management deployed $129M of net new capital in Q1 2024, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Coca-Cola: 546,500 shares worth $33.4M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 68% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Arcellx, an estimated $55.4M trimmed.

  • Suvretta Capital Management's largest Q1 2024 buy was Coca-Cola: 546,500 shares worth $33.4M.
  • Suvretta Capital Management added most to argenx in Q1 2024, an estimated $26.4M increase.
  • Suvretta Capital Management's biggest Q1 2024 reduction was Arcellx, cutting an estimated $55.4M.
  • Suvretta Capital Management fully exited Las Vegas Sands in Q1 2024, selling an estimated $36.3M.
  • Suvretta Capital Management's ten largest holdings make up 44% of its $2.69B portfolio in Q1 2024.
  • Suvretta Capital Management opened 25 new positions and closed 12 in Q1 2024.
  • Suvretta Capital Management's portfolio value rose 22% quarter-over-quarter to $2.69B.

Based on Suvretta Capital Management's 13F filing for Q1 2024, filed 15 May 2024.